Han Yi, Wang Xiao-Bin, Xiao Ning, Liu Zhi-Dong
Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University, Beijing, China.
Asian Pac J Cancer Prev. 2013;14(5):2987-90. doi: 10.7314/apjcp.2013.14.5.2987.
To explore mRNA expression and clinical significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 genes in tumor tissue of postoperative patients with non-small cell lung cancer (NSCLC).
Sixty NSCLC patients undergoing radical operation in our hospital from Nov., 2011 to Jun., 2012 were selected. Plasmid standards of ERCC1, BRCA1, RRM1, TYMS and TUBB3 were established and standard curves were prepared by SYBR fluorescent real-time quantitative PCR analysis. Samples from tumor centers were taken to detect mRNA expression of ERCC1, BRCA1, RRM1, TYMS and TUBB3 genes in cancerous tissue during operation. The total mRNA expression quantities were compared according to different clinical characteristics.
The total expression quantities of 5 genotypes from high to low were ERCC1>RRM1>TUBB3>TYMS>BRCA1 in turn. By pairwise comparisons, other differences showed statistical significance (p<0.05 or p<0.01) except for TYMS and TUBB3 (p>0.05); the low expression rates from high to low were ERCC1>TYMS>TUBB3>TUBB3>RRM1>BRCA1 in turn. The expression quantities of BRCA1, RRM1 and TYMS in males, smokers and patients without adenocarcinoma were all significantly higher than that in females, non-smokers and patients with adenocarcinoma, and significant differences were present (p<0.05 or p<0.01). In terms of pathological staging, the expression quantities of BRCA1, RRM1 and TYMS in phases IIaIIb and IIIaIIIb had a tendency to be greater than in phases I and IV.
Resistance to chemotherapy and sensitivity to targeted therapy differ among patients with NSCLC. Differences in gene expression in different individuals were also revealed. Only according to personalized detection results can individualized therapeutic regimens be worked out, which is a new direction for oncotherapy.
探讨非小细胞肺癌（NSCLC）术后患者肿瘤组织中ERCC1、BRCA1、RRM1、TYMS和TUBB3基因的mRNA表达及临床意义。
选取2011年11月至2012年6月在我院行根治性手术的60例NSCLC患者。建立ERCC1、BRCA1、RRM1、TYMS和TUBB3的质粒标准品，采用SYBR荧光实时定量PCR分析制备标准曲线。术中取肿瘤中心样本检测癌组织中ERCC1、BRCA1、RRM1、TYMS和TUBB3基因的mRNA表达。根据不同临床特征比较总mRNA表达量。
5种基因型的总表达量由高到低依次为ERCC1>RRM1>TUBB3>TYMS>BRCA1。两两比较，除TYMS与TUBB3外（p>0.05），其他差异均有统计学意义（p<0.05或p<0.01）；低表达率由高到低依次为ERCC1>TYMS>TUBB3>TUBB3>RRM1>BRCA1。男性、吸烟者及无腺癌患者的BRCA1、RRM1和TYMS表达量均显著高于女性、非吸烟者及腺癌患者，差异有统计学意义（p<0.05或p<0.01）。在病理分期方面，ⅡaⅡb期和ⅢaⅢb期的BRCA1、RRM1和TYMS表达量有高于Ⅰ期和Ⅳ期的趋势。
NSCLC患者对化疗的耐药性和对靶向治疗的敏感性存在差异。还揭示了不同个体间基因表达的差异。只有根据个性化检测结果制定个体化治疗方案，才是肿瘤治疗的新方向。
